Drug Action
Dexrazoxane is an iron chelator.
PDF page 1013
Loading InternPractice…
Drug reference
Dexrazoxane is an iron chelator.
PDF page 1013
CARDIOXANE ® Immune system and malignant disease Prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin treatment in advanced or metastatic breast cancer patients who have received a prior cumulative dose of 300 mg/m2 of doxorubicin or a prior cumulative dose of 540 mg/m2 of epirubicin when further anthracycline treatment is required ▶BY INTRAVENOUS INFUSION ▶Adult: Administer 10 times the doxorubicin-equivalent dose or 10 times the epirubicin-equivalent dose, dose to be given 30 minutes before anthracycline administration SAVENE ® Anthracycline extravasation ▶BY INTRAVENOUS INFUSION ▶Adult: Initially 1 g/m2 daily (max. per dose 2 g) for 2 days, then 500 mg/m2 for 1 day, first dose to be given as soon as possible and within 6 hours after injury
PDF page 1013
Children
PDF page 1013
Myelosuppression (effects may be additive to those of chemotherapy) CARDIOXANE ® Manufacturer advises caution in patients with heart failure—no information available. manufacturer advises caution in patients with myocardial infarction in previous 12 months—no information available. manufacturer advises caution in patients with symptomatic valvular heart disease—no information available. manufacturer advises caution in patients with uncontrolled angina—no information available
PDF page 1013
→Appendix 1: iron chelators
PDF page 1013
▶Common or very common Alopecia. anaemia. appetite decreased. asthenia. constipation. cough. diarrhoea. dizziness. drowsiness. dry mouth. dyspnoea. embolism and thrombosis. fever. gastrointestinal discomfort. headache. increased risk of infection. leucopenia. myalgia . nail disorder. nausea. neutropenia. peripheral neuropathy. peripheral oedema. post procedural infection . sensation abnormal. skin reactions. stomatitis. syncope. tachycardia. thrombocytopenia. tremor. vaginal haemorrhage. vomiting. weight decreased. wound complications ▶Uncommon Acute myeloid leukaemia. lymphoedema. sepsis. thirst. vertigo ▶Frequency not known Anaphylactic reaction
PDF page 1013
Ensure effective contraception during and for at least 3 months after treatment in men and women.
PDF page 1013
Avoid unless essential (toxicity in animal studies).
PDF page 1013
Discontinue breast-feeding.
PDF page 1013
CARDIOXANE ® Manufacturer advises caution (no information available). Dose adjustments Manufacturer advises if anthracycline dose is reduced, reduce the Cardioxane ® dose by a similar ratio. SAVENE ® Manufacturer advises avoid (no information available).
PDF pages 1013, 1014
CARDIOXANE ® DOSE ADJUSTMENTS Manufacturer advises reduce dose by 50% if creatinine clearance less than 40 mL/minute. SAVENE ® Manufacturer advises avoid—risk of accumulation.
PDF page 1014
▶Monitor full blood count. ▶Monitor for cardiac toxicity. ▶Monitor liver function. Immune system and malignant disease
PDF page 1014
Local coolants such as ice packs should be removed at least 15 minutes before administration. CARDIOXANE ® For intravenous infusion, give intermittently in Compound sodium lactate; reconstitute each vial with 25 mL water for injections and dilute each vial with 25–100 mL infusion fluid; give requisite dose over 15 minutes. SAVENE ® For intravenous infusion, give intermittently in diluent; reconstitute each 500-mg vial with 25 mL of diluent; dilute requisite dose further in remaining diluent and give over 1–2 hours into a large vein in an area other than the one affected.
PDF page 1014
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Cardioxane (Clinigen Healthcare Ltd) Dexrazoxane 500 mg Cardioxane 500mg powder for solution for infusion vials | 1 vial P £156.57 Powder and solvent for solution for infusion ELECTROLYTES: May contain Potassium, sodium ▶Savene (Clinigen Healthcare Ltd) Dexrazoxane 500 mg Savene 500mg powder for concentrate and solvent for solution for infusion vials | 10 vial P s DETOXIFYING DRUGS › UROPROTECTIVE DRUGS
PDF page 1014
Administer 10 times the doxorubicin-equivalent
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1013
Initially 1 g/m2 daily (max. per dose 2 g) for
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1013